MarketPeel
Insider Trading Intelligence
VV

Vladimir Vexler

CHRS
CHIEF SCIENTIFIC OFFICER · COHERUS ONCOLOGY, INC. · CIK 0001759506
FILING MIX · LIFETIME48%/52%
BUYS
16
SELLS
17
TOTAL VALUE
$4.53M
COMPANIES
1
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
116,361
AVG SELL PX
$15.74
TRADE KIND
SHOWING 33 / 33
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Vladimir Vexler, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%-2.06%+1.55%-3.62%-3.07%
14d3+100.00%-5.61%+0.87%-6.48%-7.08%
30d3+66.67%-3.82%+4.88%-8.70%-4.81%
60d3+33.33%+2.05%+7.74%-5.69%+0.71%
90d3+100.00%-12.22%+7.36%-19.58%-17.82%
180d3+100.00%-17.28%+16.59%-33.86%-40.44%
1y3+100.00%-12.26%+23.65%-35.91%-36.28%
2y3+100.00%-61.55%+8.31%-69.85%-71.75%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CHRS · 116,361 shares · as of Mar 31, 2023
041,90783,813125,720167,626202120222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
FLOW · 16 buys / 17 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
16,278$6.84$111.3K116,361Mar 31, 2023Apr 4, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,000131,323Jan 20, 2023Jan 24, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
3,602$10.26$37.0K91,323Jan 11, 2023Jan 12, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
3,602$9.85$35.5K94,925Jan 10, 2023Jan 12, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
5,437$9.87$53.7K98,527Jan 4, 2023Jan 6, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
80,00080,000Jan 4, 2023Jan 6, 2023View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
3,458$12.85$44.4K103,963Apr 1, 2022Apr 5, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
3,583$14.36$51.5K107,421Jan 11, 2022Jan 12, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
4,150$14.30$59.3K111,004Jan 10, 2022Jan 12, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,000115,154Jan 4, 2022Jan 6, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
80,00080,000Jan 4, 2022Jan 6, 2022View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,00073,386Apr 28, 2021Apr 30, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
114,240$16.25$1.86M53,386Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
20,3124,688Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
24,3560Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Scientific Officer
24,356$2.08$50.8K89,502Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
57,81217,188Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Scientific Officer
57,812$10.05$581.0K167,626Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Scientific Officer
20,312$9.30$188.9K109,814Mar 9, 2021Mar 11, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
50,00050,000Feb 1, 2021Feb 3, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
62,50062,500Jan 11, 2021Jan 13, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
31,25065,146Jan 11, 2021Jan 13, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
4,080$18.18$74.2K33,896Jan 10, 2021Jan 12, 2021View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
17,626$18.05$318.1K36,673Dec 10, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Scientific Officer
17,626$2.08$36.7K54,299Dec 10, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
17,62624,356Dec 10, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Scientific Officer
30,000$2.08$62.5K86,185Dec 9, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
30,00041,982Dec 9, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
49,512$18.24$903.1K36,673Dec 9, 2020Dec 11, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Scientific Officer
3,477$17.73$61.6K24,935Jan 10, 2020Jan 14, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
8,90028,412Jan 10, 2020Jan 14, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
62,50062,500Jan 10, 2020Jan 14, 2020View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
31,25056,185Jan 10, 2020Jan 14, 2020View →
Other insiders · CHRS
Loading peer insiders…
About this filer
CIK 0001759506
ROLE
Chief Scientific Officer
PRIMARY
CHRS
COMPANIES
1
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001759506DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback